MaxCyte Insider Moves: CFO’s Routine Sell vs. Executives’ Optimistic Buying Surge
MaxCyte insider activity shows a routine “sale to cover,” while executive buying signals confidence in its cell‑based pipeline and potential upside for long‑term investors.
5 minutes to read